NR-601 Final Exam Review (Weeks 5 to Week 8) (REVISED VERSION GRADED A): Primary Care of the Maturing & Aged Family Practicum - Chamberlain

Document Content and Description Below

NR-601 Primary Care of the Maturing & Aged Family Practicum Final Exam Review (Weeks 5 - 8 Content) NR601 Final Exam Review (Weeks 5 - 8 Content) Week 5 Glucose metabolism disorders • Types of diabe... tes (prediabetes, type 1 and type 2) Islet cell-specific antibodies may be identified in 70-80% of people with prediabetes & those newly dx with DM1 and hyperglycemia typically develops once 80-90% of beta cells have been destroyed. In Type I diabetes, an auto-immune attack on the beta cells of the pancreas prevents the production and secretion of insulin into the blood. Thus, Type I diabetes inhibits this first step in the insulin pathway. And since it decreases the production of insulin, it's referred to as an insulin deficiency. In DM2, drug-induced, and GDM, the pancreas continues to secrete insulin. However, it's the cells throughout the body that are unable to adequately respond to it (decrease in beta cell function), so these mechanisms inhibit the second step in the insulin pathway = insulin resistance, which can be thought of as a relative insulin deficiency. o Diagnostic criteria is based on: ketonuria, age of onset, & BMI ▪ Antibody testing and c-peptide levels determine type: Ab to islet & beta cells are present in 70-80% for Type 1 (not for Type 2), extremely low levels of c-peptide are only seen in Type 1; Type 2 usually occurs ≥ 40 y.o. & BMI > 27 with no or minimal ketonuria ▪ DX is with either 2 FBG ≥ 126 mg/dL or a random BG ≥ 200mg/dL with sx present ▪ Patients who are symptomatic & have 1 + test are dx with DM2; if asymptomatic, 2 + tests are necessary for dx (Khan videos) ▪ HbA1c ≥ 6.5 = DM2 ▪ When hyperglycemia is evident, fasting urine should be checked for ketones to determine Type 1 or 2 and the need for insulin therapy ▪ Screening recommended for anyone who is overweight and has additional risk factors. ▪ Screening should begin at 45 years old and repeated Q3 years (or frequently if multiple risk factors are present) ▪ Additional labs at dx, then annually: fasting lipid profile, eGFR, creatinine, UA, & liver function o Initial treatment recommendations for Type 2: the goal of tx is glycemic control, good nutritional status through weight management and exercise (insulin is usually considered 2nd line therapy when combo therapy fails) Show Less [Show More]

Last updated: 1 year ago

Preview 1 out of 5 pages